Ixekizumab Demonstrates High Levels of Skin Clearance among Patients with Moderate-to-Severe Plaque Psoriasis Who Did Not Respond to Treatment with Etanercept (NYSE:LLY)

- With ixekizumab, most patients who did not respond to treatment with etanercept in a Phase 3 clinical trial achieved virtually clear (Psoriasis Area Severity Index score [PASI] 90) or completely clear skin (PASI 100) after 12 weeks -

Ixekizumab Demonstrates High Levels of Skin Clearance among Patients with Moderate-to-Severe Plaque Psoriasis Who Did Not Respond to Treatment with Etanercept (NYSE:LLY)